LEISHDNAVAX (visceral leishmaniasis)

Research Areas

- Tool Development
- Biomarker Research
- Basic Research
- Data-Sharing Enabler
- Vaccine Development

At a Glance

- Status: Completed Consortium
- Year Launched: 2009
- Initiating Organization: European Commission
- Initiator Type: Government
- Location: Europe

Abstract

This project will focus on the preclinical development of a DNA vaccine for human visceral leishmaniasis. The project is based upon the DNA vaccine technology and immunomodulators developed at Mologen AG (Berlin, Germany), which are in clinical development for cancer and 3-5 known antigens that already have demonstrated profiles of protection in animal models of leishmaniasis. Antigens will be selected on the basis of preset criteria to assure protection in high proportion of target populations and against many different species of Leishmania. In vitro and in vivo models will be used to evaluate the prophylactic and therapeutic efficacy of the DNA vehicle with selected antigens alone and in combination with and without immunomodulator. Full toxicology studies will be performed on selected candidate vaccines. Training in preclinical development and clinical trials (ICH-GCP) are an important part of the proposal. Sites will be selected and ready to initiate clinical trials at the end of this project (3 years).
Mission

The focus of the EU-funded 'Development of a DNA vaccine for visceral leishmaniasis' (LEISHDNAVAX) project was to deliver a pre-clinical candidate for the development of a prophylactic and therapeutic vaccine. Research over the past few years has shown that immunity against leishmaniasis is mediated by T lymphocytes together with macrophages and dendritic cells. Based on this, LEISHDNAVAX partners designed a vaccine strategy that would mainly trigger the activation of T cells.

Structure & Governance

This consortium is the project of CORDIS (Community Research and Development Information Service), which is a program of the European Commission.

Financing

Funded by the European Commission

Data Sharing

Work produced by the consortium is owned by the European Commission

Impact/Accomplishment

To view the consortium’s final report summary, click here
LEISHDNAVAX (visceral leishmaniasis)

Links/Social Media Feed

Homepage

http://cordis.europa.eu/project/rcn/89473_en.html

Points of Contact

Administrative contact: Penny Ireland
Tel.: +44-20-79272678
Fax: +44-20-75805636

Sponsors & Partners

Mologen AG
Charite – Universitaetmedizin Berlin
Council of Scientific and Industrial Research
Institut Pasteur De Tuni
The Hebrew University of Jerusalem
Indian Council of Medical Research
Drugs for Neglected Diseases Initiative Foundation

Updated: 06/20/2017